Advisors Asset Management Inc. Acquires 3,334 Shares of Clovis Oncology, Inc. (CLVS)

Advisors Asset Management Inc. raised its holdings in Clovis Oncology, Inc. (NASDAQ:CLVS) by 175.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 5,229 shares of the biopharmaceutical company’s stock after acquiring an additional 3,334 shares during the quarter. Advisors Asset Management Inc.’s holdings in Clovis Oncology were worth $431,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in CLVS. Bank of Montreal Can increased its position in Clovis Oncology by 284.9% in the 2nd quarter. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company’s stock valued at $253,000 after acquiring an additional 2,000 shares during the period. Aperio Group LLC increased its position in Clovis Oncology by 1.7% in the 2nd quarter. Aperio Group LLC now owns 5,093 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 83 shares during the period. Sei Investments Co. increased its position in Clovis Oncology by 159.9% in the 2nd quarter. Sei Investments Co. now owns 12,239 shares of the biopharmaceutical company’s stock valued at $1,146,000 after acquiring an additional 7,529 shares during the period. TD Asset Management Inc. increased its position in Clovis Oncology by 349.8% in the 2nd quarter. TD Asset Management Inc. now owns 42,852 shares of the biopharmaceutical company’s stock valued at $4,012,000 after acquiring an additional 33,326 shares during the period. Finally, Pictet Asset Management Ltd. increased its position in Clovis Oncology by 69.0% in the 2nd quarter. Pictet Asset Management Ltd. now owns 315,663 shares of the biopharmaceutical company’s stock valued at $16,307,000 after acquiring an additional 128,852 shares during the period.

Shares of Clovis Oncology, Inc. (CLVS) opened at $57.69 on Wednesday. The company has a quick ratio of 3.16, a current ratio of 3.19 and a debt-to-equity ratio of 0.94. Clovis Oncology, Inc. has a twelve month low of $35.38 and a twelve month high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.06). The company had revenue of $16.81 million during the quarter, compared to analyst estimates of $21.12 million. Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. During the same quarter in the previous year, the business posted ($1.70) earnings per share. research analysts forecast that Clovis Oncology, Inc. will post -7.63 EPS for the current fiscal year.

Several brokerages have issued reports on CLVS. ValuEngine cut shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday. J P Morgan Chase & Co reiterated a “buy” rating on shares of Clovis Oncology in a research report on Friday, August 18th. Leerink Swann decreased their price objective on shares of Clovis Oncology to $107.00 and set an “outperform” rating for the company in a research report on Friday, August 18th. Evercore ISI assumed coverage on shares of Clovis Oncology in a research report on Wednesday, August 16th. They set an “in-line” rating and a $73.00 price objective for the company. Finally, Morgan Stanley decreased their price objective on shares of Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating for the company in a research report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company’s stock. Clovis Oncology has a consensus rating of “Buy” and an average target price of $86.15.

In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $84.54, for a total value of $253,620.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 9,000 shares of company stock valued at $653,220 over the last 90 days. Corporate insiders own 12.50% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Advisors Asset Management Inc. Acquires 3,334 Shares of Clovis Oncology, Inc. (CLVS)” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/12/06/advisors-asset-management-inc-acquires-3334-shares-of-clovis-oncology-inc-clvs.html.

Clovis Oncology Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology, Inc. (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply